Merkle Names Croom Lawrence, Senior Director, Customer Experience Lead, Life Sciences

Merkle a leading customer relationship marketing (CRM) firm and the nation’s largest privately held agency, today announced the appointment of Croom Lawrence to senior director, customer experience lead, in Merkle’s life sciences practice. Buy Casodex (Bicalutamide) pills online without prescription In this role, Lawrence will leverage Merkle’s proprietary Connected CRM™ framework to deliver innovative, data-driven digital campaigns to help world-class health brands build stronger, more profitable customer relationships.

“Croom Lawrence is an industry recognized leader who has a deep understanding of emerging digital technologies and communication channels along with strong experience working on the agency and pharmaceutical side”

“Merkle offers a quantum leap over other agencies in its class,” said Lawrence. “Merkle’s strategic, creative, and analytic teams are powered by its world-class big data capability with reach up to 95% of U.S. households and individuals. Buy Caverta (Sildenafil Citrate) tabs online without prescription This enables a more insightful, connected and holistic view of the patient journey from the perspective of each of the major stakeholders in the healthcare ecosystem, and at the individual level. As a result, Merkle is best suited for health brands who are seeking informed customer-centric strategies, creative best practices, and advanced analytics to impact and measure individual behavior across all paid, earned owned and shared channels.”
Lawrence has over 16 years’ experience as a digital and relationship marketing expert. He joins Merkle from Ironwood Pharmaceuticals, where he was the senior director, customer communication architect, who drove the planning and execution of patient and professional e-marketing for one of the industry’s largest launch brands last year. Buy Trileptal (Oxcarbazepine) without prescription Prior to joining Ironwood Pharmaceuticals, Lawrence was the VP, strategy and insights, for Wunderman/RTC Relationship Marketing. He has also served in building out the e-marketing and communications capabilities for Wyeth Pharmaceuticals and Merck & Co. In these roles, Lawrence was responsible for the integration of digital and e-marketing best practices into consumer and HCP brand initiatives.
“Croom Lawrence is an industry recognized leader who has a deep understanding of emerging digital technologies and communication channels along with strong experience working on the agency and pharmaceutical side,” said Craig Dempster, EVP, CMO, customer experience group leader, Merkle. “Croom’s background and passion for human health make him best suited to help pharmaceutical brands deliver personalized customer experiences and individual treatment plans that will help patients receive optimal care. Buy Vitamins online This appointment is a part of Merkle’s industry-specific approach to delivering Connected CRM™ solutions that help clients build sustainable competitive advantage.”
About Merkle
Merkle, a customer relationship marketing (CRM) firm, is the nation’s largest privately-held agency. For more than 25 years, Fortune 1000 companies and leading nonprofit organizations have partnered with Merkle to maximize the value of their customer portfolios. WebMD Helper By combining a complete range of marketing, technical, analytical and creative disciplines, Merkle works with clients to design, execute and evaluate connected CRM programs. With more than 1,700 employees, the privately held corporation is headquartered near Baltimore in Columbia, Maryland with additional offices in Boston; Denver; Little Rock; Minneapolis; Nanjing; New Jersey; New York; Philadelphia; Pittsburgh; San Francisco; Hagerstown, MD and Shanghai.

Karolinska Development AB (publ): Pharmanest Meets All Efficacy and Safety End Points in Phase II Study of SHACT

Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Buy Wellbutrin Sr (Bupropion) pills online without prescription Karolinska Development owns 63% of Pharmanest.
Every year, millions of women around the world experience pain and discomfort during IUD insertion (intrauterine contraception). There are few treatment options with proven efficacy and safety available to these women. Buy Vytorin (Simvastatin Ezetimibe) tabs online without prescription SHACT is a product based on an innovative formulation of lidocaine, a well-known anesthetic, and a proprietary application device developed to simplify topical application in the cervix and uterus.
Gunilla Lundmark, CEO of Pharmanest: ”The clinical evidence suggests that SHACT represents a major breakthrough for women that experience pain and discomfort during IUD insertion. Buy Proscar (Finasteride) without prescription Pain management in connection with IUD insertion represents a significant commercial opportunity alone, but as SHACT is specifically designed for topical administration we also see significant potential for other clinical uses.”
The Phase II-study with SHACT was a randomized, double-blind trial involving 218 women between 18 and 45 years of age. Data from the study shows that women that received SHACT during IUD insertion experienced a more than 30% reduction in pain, measured on a visual analogue scale (VAS), compared to patients who received placebo. Buy Vitamins online This effect was statistically significant (p < 0.0001). Patients who received SHACT also experienced less discomfort (p < 0.05) than women who received placebo. Women who received SHACT reported similar adverse events, in terms of type and frequency, as women who received placebo treatment. The most common adverse event was nausea in both treatment groups. No serious adverse events were reported.
Torbjörn Bjerke, CEO of Karolinska Development : "Pharmanest has made an extraordinary achievement, going from first human dose to clinical proof of concept in just fifteen months. PhotoMedex Board Authorizes $25 Million Share Repurchase With these positive data it is clear that SHACT has the potential to become the first safe and effective pain relief product for millions of women who use IUD."
The study, conducted in Sweden at the Karolinska University Hospital in Solna and two other sites, met all primary and secondary objectives and provides a clinical foundation for the regulatory submission of SHACT in the European Union (EU) and other countries around the world. All Best Rx : Buy drugs online
Pharmanest also reported data from a Phase I study investigating the pharmacokinetic properties of SHACT. The study showed that the majority of women had measurable levels of lidocaine after 5 minutes suggesting a rapid onset of action. FDA Approved Rx : Online Pharmacy No toxicity concerns were observed during the study.
TO THE EDITORS
About Pharmanest AB
Pharmanest is a Stockholm-based pharmaceutical company specializing in developing products for local anesthesia in gynecology and obstetrics.
About SHACT
SHACT is a proprietary 4 % lidocaine formulation developed by Pharmanest, and patent applications are pending worldwide. Drugs Rx Guide : Buy drugs online This is applied topically in the cervix and uterus with a device developed by Pharmanest. SHACT is thermogelling and becomes a gel at body temperature, which minimizes the leakage from the site of application. SHACT has a rapid onset of action and is easy to apply for healthcare professionals.
About Karolinska Development AB
Karolinska Development aims to create value for patients, researchers, and investors by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 38 projects, of which 16 are in clinical development.
Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.